NCT02817126

Brief Summary

The purpose of this study is to evaluate the safety and oncological feasibility of robot-assisted surgery for mid/low rectal carcinoma compared with laparoscopic surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,240

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

11 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 7, 2016

Completed
4 months until next milestone

First Posted

Study publicly available on registry

June 29, 2016

Completed
11 days until next milestone

Study Start

First participant enrolled

July 10, 2016

Completed
7.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

March 22, 2022

Status Verified

March 1, 2022

Enrollment Period

7.5 years

First QC Date

March 7, 2016

Last Update Submit

March 20, 2022

Conditions

Keywords

Minimally Invasive Surgical ProceduresRobotic Surgical ProceduresLaparoscopic Surgical ProceduresRectal CancerIntraoperative ComplicationsPostoperative ComplicationsRecovery of FunctionRecurrenceDisease ProgressionSurvival

Outcome Measures

Primary Outcomes (1)

  • Locoregional recurrence rate

    The proportion of patients with any cancer recurrence in the pelvic or perineal area

    3 years after surgery

Secondary Outcomes (13)

  • Circumferential resection margin positive rate

    1 week after surgery

  • Postoperative complication rate

    30 days after surgery

  • Overall survival time

    3 years after surgery

  • Disease-free survival time

    3 years after surgery

  • Operative time

    Day 1

  • +8 more secondary outcomes

Study Arms (2)

Robot-assisted surgery

EXPERIMENTAL

Patients undergo robot-assisted resections.

Procedure: Robot-assisted resection

Laparoscopic surgery

ACTIVE COMPARATOR

Patients undergo laparoscopic resections.

Procedure: Laparoscopic resection

Interventions

Arm I: Robot-assisted resection using da vinci system.

Robot-assisted surgery

Arm II: Traditional laparoscopic resection.

Laparoscopic surgery

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • American Society of Anesthesiologists (ASA) class I - III;
  • Histologically proved rectal adenocarcinoma;
  • Inferior tumor edge ≤ 10 cm from anal verge, measured by rigid rectoscopy;
  • Tumor assessed as cT1-T3 (mesorectal fascia not involved) N0-1, or ycT1-T3 Nx after preoperative radio- or chemoradiotherapy, measured by pelvic MRI;
  • No evidence of distant metastases;
  • No other malignancies in medical history except adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri;
  • Suitable for both robotic and laparoscopic surgery;
  • Informed consent.

You may not qualify if:

  • Tumors assessed as clinical complete response after preoperative radio- or chemoradiotherapy;
  • Tumors assessed as cT1N0 and suitable for local excision;
  • Signs of acute intestinal obstruction, bleeding or perforation needing emergency surgery;
  • Multiple colorectal tumors or other schedules needing for synchronous colon surgery;
  • Hereditary colorectal cancer (familial adenomatosis polyposis, Lynch Syndrome, etc.);
  • Co-existent inflammatory bowel disease;
  • Pregnancy or lactation;
  • Patients received treatment other than preoperative radio- or chemoradiotherapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (11)

Chinese PLA General Hospital

Beijing, Beijing Municipality, 100141, China

Location

The Southwest Hospital of Army Medical University

Chongqing, Chongqing Municipality, 671014, China

Location

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China

Location

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China

Location

Jilin Cancer Hospital

Changchun, Jilin, 130012, China

Location

Chinese PLA General Hospital of Northern Theatre Command (former Shenyang Military General Hospital)

Shenyang, Liaoning, 123005, China

Location

The 960th Hospital of Chinese PLA Joint Logistic Support Force (former Jinan Military General Hospital)

Jinan, Shandong, 250031, China

Location

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266003, China

Location

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200020, China

Location

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200032, China

Location

The First Affiliated Hospital of Naval Medical University (Changhai Hospital)

Shanghai, Shanghai Municipality, 200438, China

Location

Related Publications (2)

  • Feng Q, Yuan W, Li T, Tang B, Jia B, Zhou Y, Zhang W, Zhao R, Zhang C, Cheng L, Zhang X, Wei Y, Liang F, He G, Xu J; REAL Study Group. Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer: The REAL Randomized Clinical Trial. JAMA. 2025 Jul 8;334(2):136-148. doi: 10.1001/jama.2025.8123.

  • Feng Q, Yuan W, Li T, Tang B, Jia B, Zhou Y, Zhang W, Zhao R, Zhang C, Cheng L, Zhang X, Liang F, He G, Wei Y, Xu J; REAL Study Group. Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol. 2022 Nov;7(11):991-1004. doi: 10.1016/S2468-1253(22)00248-5. Epub 2022 Sep 8.

MeSH Terms

Conditions

Rectal NeoplasmsIntraoperative ComplicationsPostoperative ComplicationsRecurrenceDisease Progression

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesRectal DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsDisease Attributes

Study Officials

  • Jianmin Xu, Ph.D., M.D.

    Fudan University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Colorectal Surgery

Study Record Dates

First Submitted

March 7, 2016

First Posted

June 29, 2016

Study Start

July 10, 2016

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

March 22, 2022

Record last verified: 2022-03

Locations